These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 28535521)

  • 21. Non-renal-Related Mechanisms of FGF23 Pathophysiology.
    Hanudel MR; Laster M; Salusky IB
    Curr Osteoporos Rep; 2018 Dec; 16(6):724-729. PubMed ID: 30353318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibroblast growth factor 23/klotho axis in chronic kidney disease.
    Nitta K; Nagano N; Tsuchiya K
    Nephron Clin Pract; 2014; 128(1-2):1-10. PubMed ID: 25402964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fibroblast growth factor 23 in chronic kidney disease in children].
    Okarska-Napierała M; Skrzypczyk P; Pańczyk-Tomaszewska M
    Pol Merkur Lekarski; 2016 Jun; 40(240):393-8. PubMed ID: 27403909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FGF23: a key player in mineral and bone disorder in CKD.
    Komaba H; Fukagawa M
    Nefrologia; 2009; 29(5):392-6. PubMed ID: 19820750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FGF-23: the rise of a novel cardiovascular risk marker in CKD.
    Heine GH; Seiler S; Fliser D
    Nephrol Dial Transplant; 2012 Aug; 27(8):3072-81. PubMed ID: 22851630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
    Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
    Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGF23: a mature renal and cardiovascular risk factor?
    Zoccali C; Yilmaz MI; Mallamaci F
    Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The intersection of mineralocorticoid receptor activation and the FGF23-Klotho cascade: a duopoly that promotes renal and cardiovascular injury.
    Epstein M; Freundlich M
    Nephrol Dial Transplant; 2022 Jan; 37(2):211-221. PubMed ID: 34459924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current concepts and management strategies in chronic kidney disease-mineral and bone disorder.
    Chauhan V; Kelepouris E; Chauhan N; Vaid M
    South Med J; 2012 Sep; 105(9):479-85. PubMed ID: 22948328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic Kidney Disease-Mineral Bone Disease Biomarkers in Kidney Transplant Patients.
    Hasparyk UG; Vigil FMB; Bartolomei VS; Nunes VM; Simões E Silva AC
    Curr Med Chem; 2022 Aug; 29(31):5230-5253. PubMed ID: 35306980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease.
    Ketteler M; Biggar PH; Liangos O
    Nephrol Dial Transplant; 2013 Apr; 28(4):821-5. PubMed ID: 23233522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Women and CKD-mineral and bone disorder.
    Ho LT; Sprague SM
    Adv Chronic Kidney Dis; 2013 Sep; 20(5):423-6. PubMed ID: 23978548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble Klotho, a Potential Biomarker of Chronic Kidney Disease-Mineral Bone Disorders Involved in Healthy Ageing: Lights and Shadows.
    Martín-Vírgala J; Martín-Carro B; Fernández-Villabrille S; Ruiz-Torres MP; Gómez-Alonso C; Rodríguez-García M; Fernández-Martín JL; Alonso-Montes C; Panizo S; Cannata-Andía JB; Naves-Díaz M; Carrillo-López N
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deficiency of Soluble α-Klotho as an Independent Cause of Uremic Cardiomyopathy.
    Xie J; Wu YL; Huang CL
    Vitam Horm; 2016; 101():311-30. PubMed ID: 27125747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New Developments in CKD-MBD. Development and progression of CKD-MBD in predialysis period -when and how?].
    Komaba H
    Clin Calcium; 2014 Dec; 24(12):1771-8. PubMed ID: 25423921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The FGF23 and Klotho system beyond mineral metabolism.
    Kuro-O M
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):64-69. PubMed ID: 27838783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of activin: the other side of chronic kidney disease-mineral bone disorder?
    Cianciolo G; La Manna G; Capelli I; Gasperoni L; Galassi A; Ciceri P; Cozzolino M
    Nephrol Dial Transplant; 2021 May; 36(6):966-974. PubMed ID: 32940690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibroblast growth factor 23 and the heart.
    Faul C
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):369-75. PubMed ID: 22531163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bone metabolism and cardiovascular function update. α-klotho/FGF23 system; a new insight into the field of mineral homeostasis and the pathogeneses of aging-associated syndromes and the complications of chronic kidney disease].
    Nabeshima YI
    Clin Calcium; 2014 Jul; 24(7):37-43. PubMed ID: 24976054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5.
    Alderson HV; Ritchie JP; Middleton R; Larsson A; Larsson TE; Kalra PA
    Nephrology (Carlton); 2016 Jul; 21(7):566-73. PubMed ID: 27334353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.